Vocal Biomarkers Market Is Expected To Witness A High Growth Psychological Disorders, At A CAGR Of 15.31% From 2023-2032

Report Details:
15 Companies Covered
90 Pages
Request Free Sample

Rising Neurological and Mental Health Awareness to Drive the Global Vocal Biomarkers Market at a CAGR of 15.31% During the Forecast Period 2025 to 2035


Market Research Future (MRFR) has published a cooked research report on the “Global Vocal Biomarkers Market” that contains information from 2019 to 2035. The Vocal Biomarkers Market is estimated to register a CAGR of 15.31% during the forecast period of 2025 to 2035.


MRFR recognizes the following companies as the key players in the Global Vocal Biomarkers Market — General Mills Inc., Amway, Conagra Brands Inc., Abbott Laboratories, Kraft Foods Group Inc., Mayo Clinic, and Sonde Health Inc.


Market Highlights


The Global Vocal Biomarkers Market is accounted for to register a CAGR of 15.31% during the forecast period and is estimated to reach USD 3.27 Billion by 2035, from USD 0.68 Billion in 2025.


The market growth is primarily driven by the rising prevalence of neurological and psychological disorders, including Parkinson’s disease, Alzheimer’s disease, and depression, coupled with the growing demand for AI-enabled diagnostic technologies. Integration of artificial intelligence (AI) and machine learning (ML) into speech-based biomarkers has revolutionized diagnostic capabilities, enabling early detection of a wide range of conditions through non-invasive voice analysis.


The frequency segment dominates the market, accounting for 35% of total revenue, while hospitals and clinics remain the leading end-users, reflecting the increasing adoption of vocal biomarkers in clinical and diagnostic settings.


Moreover, the growing emphasis on mental health, the expansion of telehealth and remote monitoring solutions, and regulatory support for innovative digital health technologies are expected to further boost market expansion over the coming decade.


Segment Analysis


The Global Vocal Biomarkers Market has been segmented based on Type, End User, and Verticals.



  • Based on Type: The market is segmented into frequency, amplitude, error rate, vocal rise or fall time, phonation time, voice tremor, pitch, and others.Among these, the frequency segment dominated the market in 2024, accounting for 35% of total revenue, driven by its accuracy in mapping key speech parameters to neurological and psychological conditions. The amplitude segment is projected to be the fastest-growing, with research from the Mayo Clinic linking voice characteristics to coronary artery disease.

  • Based on End User: The market is segmented into hospitals & clinics, academic & research institutes, and others. The hospitals & clinics segment generated the most revenue in 2024, fueled by rising patient admissions and increasing use of vocal biomarkers for diagnosing cardiovascular and neurological diseases. The academic & research segment is expected to grow rapidly due to expanding R&D investments and clinical validation studies.

  • Based on Verticals: The market is categorized into psychiatric disorders (depression, attention deficit & disruptive behavior disorders, etc.), neurological disorders (Parkinson’s, Alzheimer’s, Huntington’s, etc.), respiratory disorders, cardiovascular disorders, traumatic brain injury (TBI), and others. The neurological disorders segment held the largest share in 2024, contributing 70.4% of total market revenue, driven by the rising global burden of neurological diseases. The psychiatric disorders segment is the fastest-growing category, supported by increased awareness and recognition of mental health diagnostics through voice analytics.


Regional Analysis


By Region, the Vocal Biomarkers Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).



  • North America: The North American Vocal Biomarkers Market dominated globally in 2024, owing to high adoption of voice-based technologies in diagnostics and cost-effective screening solutions. The U.S. accounted for the largest share, while Canada emerged as the fastest-growing market due to increasing research funding and AI integration in healthcare diagnostics.

  • Europe: The European Vocal Biomarkers Market held the second-largest share, driven by a rise in R&D activities and digital health initiatives across Germany, the UK, and France. The UK market is projected to grow at the fastest rate during the forecast period due to government-led healthcare innovation programs.

  • Asia-Pacific: The Asia-Pacific market is anticipated to register the highest CAGR from 2025 to 2035. The growth is attributed to the increasing prevalence of mental health and neurological disorders, technological advancement in digital health tools, and expanding collaborations with global players. China accounted for the largest share, while India was the fastest-growing market in the region.


Industry Developments



  • March 2021: Sonde Health partnered with Xavier University Center for Population Health to evaluate its vocal biomarker platform for screening COVID-19 symptoms.

  • June 2021: Medable’s Cancer Moonshot Program collaborated with Aural Analytics to utilize voice data for assessing cancer patients remotely via digital biomarkers, under the U.S. NIH Beau Biden Cancer Moonshot initiative.

  • October 2020: Mayo Clinic partnered with Vocalis Health to develop voice-based tools for detecting pulmonary hypertension and monitoring patient health.

  • October 2021: Sonde Health launched Sonde Mental Fitness, a voice-enabled mental health monitoring tool that evaluates emotional well-being through AI-based voice analysis.

  • 2023–2024: Research initiatives led by Weil Cornell Medicine, University of South Florida, and UniversitĂ© de MontrĂ©al, backed by the U.S. National Institutes of Health (NIH), are advancing speech biomarkers for clinical care, supported by a USD 14 million grant.


Market Drivers



  • Advancements in AI and Machine Learning: Integration of AI enhances precision in analyzing voice parameters for early disease detection.

  • Rising Neurological and Psychological Disorders: Over 1 billion people globally suffer from neurological conditions, creating a strong demand for diagnostic innovations.

  • Increasing Awareness of Mental Health: Mental wellness recognition under the UN Sustainable Development Goals is expanding the market scope.

  • Telehealth and Remote Monitoring: The growing adoption of virtual care is accelerating the use of voice-based diagnostics.

  • Regulatory Support: Evolving health-tech approval frameworks are enabling faster commercialization of vocal biomarker solutions.


Key Findings of the Study



  • The Global Vocal Biomarkers Market is projected to reach USD 3.27 Billion by 2035, growing at a CAGR of 15.31% during the forecast period (2025–2035).

  • North America accounted for the largest market share in 2024, while Asia-Pacific is projected to be the fastest-growing region.

  • Frequency-based biomarkers dominate the type segment, accounting for 35% of market revenue.

  • Hospitals & clinics are the leading end-user category, driven by high patient admissions and diagnostic applications.

  • Key market players include General Mills Inc., Amway, Conagra Brands Inc., Abbott Laboratories, Kraft Foods Group Inc., Mayo Clinic, and Sonde Health Inc.


Related Reports


https://www.marketresearchfuture.com/reports/vocal-biomarkers-market-3933